Revolutionising Cancer Detection, Ensuring Precision Therapy, and Energizing Drug Discovery.
We are pioneering cancer screening methods, providing ultra-personalized insights, and accelerating novel target discovery.
Our Discoveries:
8800+
unique biomarkers to detect lung, pancreatic, breast, and ovarian cancer early
1100+
unique biomarkers to detect metastatic breast cancer early
4000+
unique biomarkers to predict response to therapies for melanoma, lung cancer, and ovarian cancer
We are actively pursuing the discovery of distinctive biomarkers that can detect primary/recurrent cancer early and definitively predict response to cancer therapies for global leading cancers. We discover novel targets in difficult-to-treat cancers.
Our Mission
We will revolutionise cancer detection and care by discovering molecular patterns that define each patient from diagnosis to cure. These ultra-personalised patterns will ensure the best possible treatment, one patient at a time thus giving each patient the best possible life span and quality of life. We will supercharge drug discovery utilizing our penetrating insights into cancer biology.
Our Vision
Detect early, help treat right, every patient, every time.
Our Services
Cutting-edge bioinformatics platform to relate clusters of biomarkers to clinical phenotypes.
Precise, definitive predictions of response to therapies for effective cancer treatment planning.
Minimally invasive methods for primary and recurrent cancer screening.
Achievements & Recognition
Start-up India Seed Fund
The Startup India initiative of the Government of India envisages building a robust Start-up ecosystem in the country to nurture innovation and provide opportunities to budding entrepreneurs. We were selected for investment as a promising startup with a disruptive, innovative solution in oncology diagnostics.
National Bio Entrepreneurship Competition (NBEC 2024)
NBEC is a nationwide competition to attract, identify, and nurture bio-entrepreneurs working on novel, scalable business ideas with significant societal impact. Out of 3,300+ applicants and several assessment rounds, we were selected to be one of the 24 finalists. This award has only strengthened our resolve to revolutionise cancer diagnostics, with the ultimate goal of improving lives and advancing patient care.
News
Trucan has partnered with HealthCare Global Enterprises (HCG), India’s leading cancer care provider, to validate its cutting-edge diagnostic tests for early cancer detection, pre-treatment response prediction, ultra-personalized treatment planning, and therapy response monitoring. These advanced tests, powered by next-generation sequencing and biomarker-driven technologies, are designed to address critical gaps in oncology by early detection and improving accuracy in predicting treatment responses to a variety of conventional and targeted therapies.
This collaboration will see Trucan technologies being validated at HCG’s Triesta Genomics Laboratories thus generating real world evidence prior to adoption into clinical practice. Together, the partners aim to make precision oncology accessible and affordable, tailored to the unique needs of Indian patients while meeting global standards.
We look forward to sharing the outcomes of this collaboration and demonstrating how our innovations have reshaped the cancer care landscape, delivering meaningful benefits to patients and healthcare providers alike.
Read the full press release at: https://drive.google.com/file/d/1wwIPkZ0BtlBpdB8F11zk5w-36lND99kb/view?usp=sharing
